Navigation Links
Bioniche Reports Fiscal 2008 Third Quarter
Date:5/9/2008

- sales increase over Q3 '07; gross profit remains stable; net loss per

share improves -

(all figures are in Canadian dollars unless otherwise noted)

BELLEVILLE, ON, May 9 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for the third quarter of its 2008 fiscal year, ending March 31, 2008.

"One highlight of our third quarter was the notification by the U.S. Department of Agriculture (USDA) that our E. coli O157:H7 cattle vaccine is eligible for a conditional license," said Graeme McRae, President & CEO of Bioniche Life Sciences Inc. "Another important event was the granting by the U.S. Food and Drug Administration (FDA) of a Fast Track designation for our second Phase III clinical trial in bladder cancer with our proprietary Mycobacterial Cell Wall-DNA Complex (MCC) - trademarked Urocidin. These regulatory breakthroughs are significant in facilitating market access for our two priority technologies."

Fiscal 2008 Third Quarter Financial Results Highlights

For the three-month and nine-month periods ended March 31, 2008, consolidated revenues totalled $7.2 million and $19.6 million respectively, compared to $6.4 million and $20.1 million for the corresponding periods in Fiscal 2007. The increase in sales in the current quarter reflects increased sales of animal health products in the U.S. and export markets.

For the three-month and nine-month periods ended March 31, 2008, overall gross profit totalled $4.2 million and $11.4 million respectively, compared to $3.7 million and $11.4 million for the corresponding periods in Fiscal 2007. For the three-month and nine-month periods ended March 31, 2008, overall gross profit as a percentage of sales remained stable at 57.8% and 58.2% respectively, compared to 58.2% and 57.1% for the corresponding periods in Fiscal 2007. The gr
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Bioniche Appoints U.S. President of Food Safety
2. Bioniche Reports the Passing of its Board Chair
3. Bioniche Converts a Portion of its Debt to Equity
4. Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy
5. Bioniche Pharma Chooses TrackWise for its Deviation Control Solution
6. Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM)
7. Bioniche Reports Fiscal 2008 Second Quarter
8. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
9. Bioniche Amends Terms of Convertible Debt with Laurus Master Funds
10. Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario
11. Bioniche Reports Fiscal 2008 First Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... HealthDay Reporter , TUESDAY, July 29, 2014 (HealthDay ... stage for harmful health habits, including eating disorders, according to ... to 2012 also found a link between early dieting and ... was when she started her first diet, the more likely ... like vomiting or laxative misuse," said study researcher Lauren Holland, ...
(Date:7/30/2014)... Researchers from the University of So Paulo (USP) have ... no instructions for the production of a protein, modulates ... of apoptosis, or programmed cell death. , According ... and coordinator of a research funded by So Paulo ... cancer cells, and methods that are capable of stimulating ...
(Date:7/30/2014)... We know pregnancy cravings don’t always inspire the ... cream—but the latest episode of the Telly Award-winning web series ... has a recipe that is delicious, satisfying and, most of ... serves up an easy recipe that supports a healthy diet ... Rasika, which was named one of the 20 top-rated restaurants ...
(Date:7/30/2014)... Chinese researchers say a protein that makes up ... used as a prognostic indicator in people on chemotherapy for ... article on the study , just posted on the Surviving ... Medicine at Shandong University Hospital in China analyzed the albumin ... 1995 and 2013. They found that, the lower the albumin ...
(Date:7/30/2014)... Seattle, Wa (PRWEB) July 30, 2014 It is ... as they would want to be in life is because they ... However, as recent research shows, this belief is only an ... they can achieve more had they been only “smarter”. , So, ... but also by one’s willingness to work hard for that success. ...
Breaking Medicine News(10 mins):Health News:Dieting at Young Age Often Backfires, Study Says 2Health News:Dieting at Young Age Often Backfires, Study Says 3Health News:Brazilian researchers identify RNA that regulates cell death 2Health News:Brazilian researchers identify RNA that regulates cell death 3Health News:What to Eat When You’re Expecting 2Health News:Study Finds Common Blood Protein May Predict Mesothelioma Survival, Reports Surviving Mesothelioma 2Health News:Brain Evolution System - #1 Brainwave Entrainment Meditation Program Review | Unleashing One’s Ultimate Potential Improving Mind Power – Vinamy 2Health News:Brain Evolution System - #1 Brainwave Entrainment Meditation Program Review | Unleashing One’s Ultimate Potential Improving Mind Power – Vinamy 3
... Alliance Medical Plans, Inc., a leading provider-sponsored health insurer, ... and Iowa, has announced positive outcomes from a nine-month ... makers of Actonel, a prescription drug for the treatment ... with Health Alliance, the makers of Actonel agreed to ...
... Psoriasis Foundation asks Americans affected by psoriatic diseases to take ... Today is World Psoriasis Day and the National Psoriasis ... arthritis to raise awareness about these diseases by going to ... , Psoriasis, a painful and disfiguring autoimmune disease that appears ...
... Ads focus on regulations scheduled for Nov. 1 ... Cardiology (ACC) and the Cardiology Advocacy Alliance (CAA) today ... halt Medicare regulations that will restrict patients, access to ... Services (CMS), which runs the Medicare program, is scheduled ...
... SAN DIEGO, Oct. 28 BioMed Realty Trust, Inc. (NYSE: ... Providing Real Estate to the Life Science Industry®, today announced ... 30, 2009. , (Logo: http://www.newscom.com/cgi-bin/prnh/20091005/BIOMEDLOGO ) , ... quarter to $93.0 million, up 15.1% from $80.8 million for ...
... 28 The House Judiciary Committee today called upon ... and sport to better understand the effects of head ... Nationally recognized sports physician and neurosurgeon, Julian E. Bailes, ... decades of research detailing how repetitive head trauma on ...
... N.Y., Oct. 28 What happens when intended parents cross ... Vinay Menon of Mumbai, India-based law firm Menon & Associates ... Proactive Family Solutions was among the panel ... American Bar Association Section of Family Law recently held in ...
Cached Medicine News:Health News:Health Alliance Announces Promising Nine-Month Results from First Ever Outcome-Based Reimbursement Program for Actonel(R) (risedronate sodium) Tablets 2Health News:Health Alliance Announces Promising Nine-Month Results from First Ever Outcome-Based Reimbursement Program for Actonel(R) (risedronate sodium) Tablets 3Health News:Health Alliance Announces Promising Nine-Month Results from First Ever Outcome-Based Reimbursement Program for Actonel(R) (risedronate sodium) Tablets 4Health News:Millions Mark World Psoriasis Day on Oct. 29 2Health News:Cardiology Groups Implore President Obama: Stop Medicare Rule That Will Restrict Access to Heart Care 2Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 2Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 3Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 4Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 5Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 6Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 7Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 8Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 9Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 10Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 11Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 12Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 13Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 14Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 15Health News:House Judiciary Committee Hearing Calls Attention to Long-Term Effects of Head Injury Among NFL Players 2Health News:Legislation in India to Address Assisted Reproductive Technology, Egg Donation and Surrogacy 2
(Date:7/30/2014)... N.J. and SAN DIEGO , ... (NASDAQ: ARNA ) announced today that an article ... trials of lorcaserin entitled, "Early Weight Loss While on Lorcaserin, ... Outcomes," was recently published in the online issue of ... Society. The objective of these analyses was to identify whether ...
(Date:7/30/2014)...  Hospira, Inc. (NYSE: HSP ), ... infusion technologies, today reported results for the second ... the quarter were $1.1 billion and adjusted* diluted ... specified items as described later in this press ... Generally Accepted Accounting Principles (GAAP) basis, second-quarter 2014 ...
(Date:7/30/2014)... 2014 Company expands reach ... to big data, aerospace and defense, medical, and ... leading engineering R&D services company, today announced professional ... solutions for aerospace and defense , ... industrial , and visual computing ...
Breaking Medicine Technology:Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30
... Inc.,(Nasdaq: VRUS ), a clinical stage pharmaceutical ... to treat viral,infections, reported unaudited financial results for ... 2007. Pharmasset reported a net loss,attributable to common ... the first fiscal quarter of 2008, as compared ...
... and MONTREAL, Feb. 14 Pharmion,Corporation (Nasdaq: ... announced,that the U.S. Food and Drug Administration (FDA) ... as an Orphan,Drug for the treatment of acute ... designation require that the product be intended for,treatment ...
Cached Medicine Technology:Pharmasset Reports First Fiscal Quarter 2008 Financial Results 2Pharmasset Reports First Fiscal Quarter 2008 Financial Results 3Pharmasset Reports First Fiscal Quarter 2008 Financial Results 4Pharmasset Reports First Fiscal Quarter 2008 Financial Results 5Pharmasset Reports First Fiscal Quarter 2008 Financial Results 6Pharmasset Reports First Fiscal Quarter 2008 Financial Results 7Pharmasset Reports First Fiscal Quarter 2008 Financial Results 8Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4
Solid lower plate with outside width 15 mm. Open serrated upper plate with inside dimensions 9 x 12 mm. Serrated handle with locking thumb screw and polished finish....
Narrow smooth jaws. Serrated handle with polished finish....
14 mm oval solid lower plate and straight 9 mm serrated upper jaw. Locking thumb screw and serrated handle with polished finish....
Round solid 10 mm wide lower plate. Open upper plate with inside diameter 8 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
Medicine Products: